Related Experiment Video
Updated: May 13, 2026
08:20
A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization
Published on: September 2, 2021
Development and evaluation of a pharmacogenomics educational program for pharmacists
Christine M Formea1, Wayne T Nicholson, Kristen B McCullough
1Department of Pharmacy Services, Mayo Clinic, Rochester, MN 55905, USA. formea.christine@mayo.edu
American Journal of Pharmaceutical Education
|March 6, 2013
Summary
Pharmacists showed a small improvement in pharmacogenomics knowledge after a continuing education program. However, overall knowledge retention was marginal, indicating a need for more extensive pharmacogenomics education.
Area of Science:
- Pharmacogenomics
- Continuing Pharmacy Education
Background:
- Pharmacogenomics (PGx) is an emerging field in personalized medicine.
- Pharmacists play a crucial role in implementing PGx into clinical practice.
- Assessing pharmacists' knowledge is vital for effective PGx integration.
Purpose of the Study:
- To evaluate the impact of a targeted, case-based continuing education program on pharmacists' pharmacogenomics knowledge.
- To assess knowledge retention 2 months post-intervention.
Main Methods:
- An 11-question electronic survey was administered to 272 pharmacists.
- Pretest and posttest scores were compared before and 2 months after the educational intervention.
- The study was conducted within a large, academic healthcare system.
Main Results:
- Pharmacists' average test scores improved from 46% to 53% (p=0.0003).
- This represents an average improvement of 0.7 questions.
- The improvement suggests initial knowledge gain from the educational program.
Conclusions:
- While the educational program led to a statistically significant improvement in pharmacogenomics knowledge, the overall retention was marginal.
- The complex nature of pharmacogenomics necessitates substantial educational initiatives.
- Further efforts are required to enhance pharmacists' knowledge and confidence in applying pharmacogenomics.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...